What kind of research does your lab generally focus on?
Our lab conducts translational studies related to novel immunotherapies. We do pre-clinical studies aimed at developing new regimens beyond inhibitors of PD-1 and CTLA-4 and studies of toxicities of immunotherapies. We also conduct studies of novel regimens for brain metastasis.
What were some of the challenges making the switch from working in the lab on campus to working remotely?
Many ongoing studies had to be stopped in the middle, including costly studies in mice. A number of experiments will have to be started from scratch when we return to work. Although it's been disruptive, the upside is this provides an opportunity to rethink research priorities and engage in intellectual interactions with fellow lab members and other researchers.
Have you ever had to do this before?
Luckily, no.
How are you staying connected with your co-workers from your lab?
I communicate with all members of the lab by phone or videoconferencing once or twice a week. We are also conducting regular group meetings by Zoom.
What are your biggest worries concerning your ongoing research/future research?
The pause in bench research will certainly hamper productivity. This is particularly difficult for trainees.
You also care for patients with melanoma and renal cell carcinoma. How are you transitioning their care during this time?
All patients on active treatment are still being seen before treatment. We are doing our best to space out treatments when appropriate. Patients in follow-up are either assessed by video conferencing or we are postponing their appointments to a later date.
Are there any advantages working remotely?
One advantage is the opportunity to read more and engage in scientific discussions with others, which is always a plus.